Published in Drug Law Weekly, June 2nd, 2009
"We are very pleased with the panel's decision which affirms our right to market Ferrlecit(R) and allows us to continue our commitment to the nephrology community," said Paul Bisaro, Watson's President and Chief Executive Officer....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.